Drug treatment of epilepsy: Options and limitations

The modern antiepileptic drug (AED) era--spanning a period of more than 150 years from the first use of bromide in 1857 to 2008--has seen the introduction into clinical practice of a diverse group of effective and safe drugs. These AEDs have provided considerable benefits for those afflicted with epilepsy of all kinds. In as many as 60-70% of newly treated patients, current AEDs lead to satisfactory control of seizures and a favorable risk-benefit balance for the great majority of patients, albeit with considerable differences in response depending on the type of seizure and epilepsy syndrome and rare serious adverse events. Unfortunately, in 20-30% of patients, epilepsy cannot be controlled. Patients with drug-resistant epilepsy often have serious comorbidity, including injury, depression, anxiety, and increased mortality. The aim of antiepileptic treatment should be to control seizures as quickly as possible with no or minimal side effects and with no negative impact on the quality of life. Improved seizure control is likely to reduce the morbidity and increased mortality associated with uncontrolled epilepsy. In this short overview, the options and the limitations of treating patients with epilepsy are briefly summarized.

[1]  A. Marson,et al.  Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial , 2005, The Lancet.

[2]  Markus Reuber,et al.  Anxiety in patients with epilepsy: Systematic review and suggestions for clinical management , 2005, Epilepsy & Behavior.

[3]  Dieter Schmidt,et al.  Drug Resistance in Epilepsy: Putative Neurobiologic and Clinical Mechanisms , 2005, Epilepsia.

[4]  S. Lydersen,et al.  Rash from Antiepileptic Drugs: Influence by Gender, Age, and Learning Disability , 2007, Epilepsia.

[5]  Jing Shen,et al.  The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[6]  Dieter Schmidt,et al.  Experimental and Clinical Evidence for Loss of Effect (Tolerance) during Prolonged Treatment with Antiepileptic Drugs , 2006, Epilepsia.

[7]  Dieter Schmidt,et al.  Modern management of epilepsy: A practical approach , 2008, Epilepsy & Behavior.

[8]  M. Benedetti.  Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies , 2000, Fundamental & clinical pharmacology.

[9]  M. Sillanpää,et al.  Prognosis of seizure recurrence after stopping antiepileptic drugs in seizure-free patients: A long-term population-based study of childhood-onset epilepsy , 2006, Epilepsy & Behavior.

[10]  E. Perucca,et al.  Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs , 2003, The Lancet Neurology.

[11]  Discontinuing antiepileptic drugs in children with epilepsy , 1995 .

[12]  H. Todt.  The Late Prognosis of Epilepsy in Childhood: Results of a Prospective Follow‐up Study , 1984, Epilepsia.

[13]  W. Löscher,et al.  New Developments in Antiepileptic Drug Resistance: An Integrative View , 2009, Epilepsy currents.

[14]  W. Löscher,et al.  The clinical impact of pharmacogenetics on the treatment of epilepsy , 2009, Epilepsia.

[15]  B. Bourgeois,et al.  Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society , 2004 .

[16]  Jean-Pierre Daurès,et al.  The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population‐based study in a Western European country , 2008, Epilepsia.

[17]  D. Chadwick,et al.  Randomised study of antiepileptic drug withdrawal in patients in remission , 1991, The Lancet.

[18]  G. Zaccara,et al.  Idiosyncratic Adverse Reactions to Antiepileptic Drugs , 2007, Epilepsia.

[19]  D. Schmidt.  Single drug therapy for intractable epilepsy , 2004, Journal of Neurology.

[20]  A. Berg,et al.  Relapse following discontinuation of antiepileptic drugs , 1994, Neurology.

[21]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[22]  B. Bourgeois,et al.  Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New‐Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society , 2004, Epilepsia.

[23]  S. A. Gromov,et al.  Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial , 2003, Epilepsy Research.

[24]  M. Tennison,et al.  Discontinuing antiepileptic drugs in children with epilepsy. A comparison of a six-week and a nine-month taper period. , 1994, The New England journal of medicine.

[25]  B. Uthman,et al.  New onset geriatric epilepsy , 2005, Neurology.

[26]  Timothy A. Pedley,et al.  Epilepsy : a comprehensive textbook , 2008 .

[27]  B. Uthman,et al.  Topiramate in older patients with partial‐onset seizures: A pilot double‐blind, dose‐comparison study , 2008, Epilepsia.

[28]  F. Andermann,et al.  Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures , 2008, Neurology.

[29]  B. Bourgeois,et al.  Efficacy and Tolerability of the New Antiepileptic Drugs, I: Treatment of New‐Onset Epilepsy: Report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society , 2004, Epilepsia.

[30]  Simon Shorvon,et al.  Handbook of Epilepsy Treatment , 2000 .

[31]  Y. Schiller,et al.  Quantifying the response to antiepileptic drugs , 2008, Neurology.

[32]  B. Bourgeois,et al.  Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy , 2004, Neurology.

[33]  W. Hauser.  The natural history of drug resistant epilepsy: epidemiologic considerations. , 1992, Epilepsy research. Supplement.

[34]  Shlomo Shinnar,et al.  How long does it take for epilepsy to become intractable? A prospective investigation , 2006, Annals of neurology.

[35]  David F. Smith,et al.  The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial , 2007, The Lancet.

[36]  E. Zalneraitis,et al.  Neurologic and neuro pathologic findings associated with marantic endo carditis in children and young adults , 1980 .

[37]  D. Schmidt,et al.  Monotherapy versus Polytherapy in Epilepsy , 1995 .

[38]  Scott B Patten,et al.  Psychiatric Comorbidity in Epilepsy: A Population‐Based Analysis , 2007, Epilepsia.